Velagliflozin Proline Monohydrate

Verify with FDA CVM →

3,392 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
3,392
Total Reports
260
Deaths Reported
770.0%
Death Rate

Active Ingredients

Velagliflozin Proline Monohydrate

Administration Routes

OralUnknownTopicalSubcutaneousParenteralUnassignedPerineural

Species Affected

Cat 3,136
Unknown 179
Dog 70
Human 6
Lynx 1

Most Affected Breeds

Domestic Shorthair 2,165
Domestic Longhair 275
Cat (unknown) 258
Unknown 199
Domestic Mediumhair 194
Beagle 68
Siamese 65
Maine Coon 44
Ragdoll 18
Russian 14

Most Reported Reactions

Ketosis 1,089
Lack of efficacy - NOS 760
Weight loss 710
Diarrhoea 543
Vomiting 469
Ketonuria 420
Lethargy (see also Central nervous system depression in Neurological) 419
Anorexia 299
Death by euthanasia 206
Elevated blood urea nitrogen (BUN) 170
Hypokalaemia 160
Dehydration 146

Outcome Breakdown

Outcome Unknown
2,278 (70.9%)
Recovered/Normal
377 (11.7%)
Ongoing
298 (9.3%)
Euthanized
206 (6.4%)
Died
54 (1.7%)

Data Summary

Metric Value
Total adverse event reports 3,392
Reports involving death 260
Case-fatality rate (reported events) 770.0%
Distinct species in reports 5
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Velagliflozin Proline Monohydrate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 3,392 adverse event reports referencing Velagliflozin Proline Monohydrate, including 260 reports in which the animal died — a 770.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Velagliflozin Proline Monohydrate. Reported administration routes include Oral, Unknown, Topical, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Velagliflozin Proline Monohydrate reports are Cat (3,136 reports), Unknown (179 reports), Dog (70 reports), with Cat accounting for the largest share. Within those species, Domestic Shorthair (2,165), Domestic Longhair (275), Cat (unknown) (258) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Velagliflozin Proline Monohydrate are Ketosis (1,089), Lack of efficacy - NOS (760), Weight loss (710), Diarrhoea (543). Of the 3,213 reports with a coded outcome, Outcome Unknown is the leading category at 70.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Velagliflozin Proline Monohydrate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial